I-Mab, TRACON Pharmaceuticals begins human trial of CD73 antibody TJD5
Category: #health  By Pankaj Singh  Date: 2019-08-03
  • share
  • Twitter
  • Facebook
  • LinkedIn

I-Mab, TRACON Pharmaceuticals begins human trial of CD73 antibody TJD5

The study will evaluate the tolerability and safety of TJD5 and determine recommended doses for future clinical studies.

I-Mab Biopharma (I-Mab), a clinical stage biopharmaceutical firm focused on the discovery and development of biologics in immuno-oncology, has announced that cancer drug maker TRACON Pharmaceuticals has dosed its first patient in a U.S. Phase 1 first-in-human clinical trial of CD73 antibody TJD5, a proprietary of I-Mab, in patients with advanced solid tumors.

According to reports, the company will dose TJD5 in the 1st Phase of its trials, both as a single agent and in combination with TECENTRIQ®, a PD-L1 antibody retailed by Roche. For the record, I-Mab and Roche entered into a research collaboration on April 2019, where Roche agreed to supply TECENTRIQ® to I-Mab for testing in combination with TJD5 in a clinical study.

Speaking on the announcement, Joan Shen, M.D., Ph.D., Head of R&D, I-Mab Biopharma, said that TJD5 is the third internally discovered drug developed by the company to enter clinical studies in the U.S. She said that the ‘Fast-to-PoC Global Approach’ plays an essential role for advancing the company’s proprietary drug candidates towards acceptance in the U.S, which further deepens their partnership with TRACON.

Shen added that the treatment resistance to PD-L1/ PD-1 inhibitors are one of the key challenges across cancer types and the company hopes the combination of TECENTRIQ® and TJD5 will offer a new treatment option to counter the unmet medical needs.

According to Charles Theuer, M.D., Ph.D., President and CEO, TRACON Pharmaceutical, signing this partnership contract with I-Mab is an essential milestone as both the parties have expanded their immune-oncology pipeline and validated TRACON’s product manufacturing capabilities designed to lower the time and cost of clinical development for its partners.

He said that their firm will continue to work with I-Mab to optimize the clinical development of TJD5, an antibody with best-in-class, global potential.

Source Credit: http://www.i-mabbiopharma.com/en/article-321.aspx

 

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Escorts amps CAPEX to $51Mn for FY23; expects high e-tractors exports
Escorts amps CAPEX to $51Mn for FY23; expects high e-tractors exports
By Pankaj Singh

Escorts Ltd., an Indian engineering company that operates in the sectors of agricultural machinery, construction machinery, and railway equipment, has reportedly arranged CAPEX of around Rs 400 crore (USD 51 Million) for the current financial year in...

Hillstone unveils cloud workload protection platform ‘CloudArmour’
Hillstone unveils cloud workload protection platform ‘CloudArmour’
By Pankaj Singh

Hillstone Networks, an IT service management company, has recently announced the launch of its all-inclusive cloud workload protection platform (CWPP), Hillstone CloudArmour. According to sources, CloudArmour offers Hillstone’s enterprise-grad...

Whatfix announces takeover of Leap.is to extend mobile capabilities
Whatfix announces takeover of Leap.is to extend mobile capabilities
By Pankaj Singh

Whatfix, a SaaS-based platform that offers in-app guidance & performance support for web applications and software products, has recently announced that it is acquiring mobile-first onboarding and assistance platform, Leap.is (formerly known as J...